journal articles
CORRIGENDUM TO “LECANEMAB FOR TREATMENT OF INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE (AD) WHO ARE APOLIPOPROTEIN E Ε4 (APOE Ε4) NON-CARRIERS OR HETEROZYGOTES” [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE (2026) 100507]
Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich
J Prev Alz Dis 2026;4(13)
CITATION:
Richard Perry ; Christopher Kipps ; Maria Eugenia Soto Martín ; Marco Bozzali ; Giancarlo Logroscino ; Sarah Trafford ; Shobha Dhadda ; Michio Kanekiyo ; Amanda Goodwin ; Mark Hodgkinson ; Steven Hersch ; Michael Irizarry ; Lynn Kramer ; Lutz Froelich (2026): Corrigendum to “Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes” [The Journal of Prevention of Alzheimer's Disease (2026) 100507]. The Journal of Prevention of Alzheimer’s Disease (JPAD). https://doi.org/10.1016/j.tjpad.2026.100527